Pasithea Therapeutics (KTTA) Expected to Post Quarterly Earnings on Thursday

Pasithea Therapeutics (NASDAQ:KTTA) is projected to issue its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Pasithea Therapeutics to announce earnings of ($0.21) per share and revenue of $0.20 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Pasithea Therapeutics (NASDAQ:KTTA) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16). On average, analysts expect Pasithea Therapeutics to post ($0.76) EPS for the current fiscal year and ($0.46) EPS for the next fiscal year.

Pasithea Therapeutics Price Performance

Shares of NASDAQ KTTA opened at $0.54 on Tuesday. The firm has a fifty day moving average of $0.48 and a 200 day moving average of $0.62. Pasithea Therapeutics has a one year low of $0.28 and a one year high of $2.06.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on KTTA. Zacks Research lowered shares of Pasithea Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Pasithea Therapeutics in a research report on Monday, September 21st. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $3.00.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp. is a biotechnology company focused on developing treatments for central nervous system (CNS) disorders. Its research has centered on novel therapies for conditions such as depression and other neuropsychiatric diseases, areas in which existing treatments may not provide adequate results for all patients.

The company has also pursued psychedelic-based therapeutic approaches and related clinical-development programs. In addition to drug discovery, Pasithea has explored treatment-delivery activities, including ketamine-assisted therapy services through operations associated with its business.